Hong Kong Stock Afternoon Review | Hang Seng Index fell 1% in early trading, Kuaishou reversed the market and led blue chips

The Zhitong Finance App learned that the Hong Kong stock Hang Seng Index fell 1%, down 256 points to 25,310 points; the Hang Seng Technology Index fell 0.76%. Hong Kong stocks traded HK$133.2 billion in early trading.

Kuaishou-W (01024) rose 4.82%, leading the blue chip increase. Keling AI received another investment of more than 1.5 billion yuan, and the National Artificial Intelligence Fund and Chia Tai Robotics took shares.

MINIMAX-W (00100) rose more than 6%, H3 Max crossed the real-time live streaming threshold, and AI live streaming is expected to land.

Minglue Technology-W (02718) increased by more than 9%. Revenue from intelligent integrated services increased more than 6 times in the first half of the year, and the company entered the smart circuit.

Haizhi Technology (02706) increased by more than 14%, and revenue surged 70.4% in the first half of the year. Atlas Smart is the main engine of growth.

Kingsley Biotech (01548) rose more than 8%. Demand for AI led to growth in the life sciences sector, and the company raised its guidelines sharply.

Basic Semiconductors (09971) rose more than 5%, and the company achieved a milestone of improving gross margin. Mid-term industrial module revenue surged 2825.1% year on year.

Dekang Agriculture and Animal Husbandry (02419) rose by more than 7%, and pigs stood strong at the 11 yuan mark. The company is expected to face an inflection point in performance and valuation reshaping.

Huaxin Construction (06655) rose more than 10%, net profit to mother increased 55.22% year-on-year in the medium term, and overseas business continued to grow steadily.

Junzhi Group (01300) rose more than 11%, and net profit increased 7.35 times year-on-year in the first half of the year. The company benefited from rapid growth in the global AIDC industry.

Fubo Group (03738) has increased by more than 8%, rising more than 40% in the past six days, and the AI creation platform has entered the commercialization stage.

The IPO Xiying-W (00625) was listed on the first day. At one point, the intraday break fell by more than 9%, and fell more than 4% in midday trading. Revenue growth has slowed, and listing valuations have shrunk 70% from their peak.

Jiangxi Biotech (06915) fell by more than 10%. Net profit for the first half of the year decreased by 61% year on year, and revenue fell by about 16.5%.